Bristol-Myers Squibb Company (BMY)

75.68
NYSE : Health Care
Prev Close 75.50
Day Low/High 75.00 / 75.98
52 Wk Low/High 51.82 / 77.12
Avg Volume 5.95M
Exchange NYSE
Shares Outstanding 1.67B
Market Cap 126.03B
EPS 0.90
P/E Ratio 37.56
Div & Yield 1.52 (2.00%)

Latest News

Bristol-Myers Squibb Announces Availability Of FDA-Approved ORENCIA® (abatacept) ClickJect™, A Self-Administered Subcutaneous Autoinjector, For Adults With Moderate To Severe Rheumatoid Arthritis

Bristol-Myers Squibb Announces Availability Of FDA-Approved ORENCIA® (abatacept) ClickJect™, A Self-Administered Subcutaneous Autoinjector, For Adults With Moderate To Severe Rheumatoid Arthritis

Bristol-Myers Squibb Company (NYSE:BMY) announced today the commercial launch of the ORENCIA ClickJect TM Autoinjector, a new self-administered autoinjector for adults with moderate to severe rheumatoid arthritis...

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.

Jim Cramer — J&J Is an Absolutely Terrific Stock

Jim Cramer — J&J Is an Absolutely Terrific Stock

Jim Cramer is impressed by Johnson & Johnson's continual growth.

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Cramer: These Stocks Are the Key to the Bull Market

Cramer: These Stocks Are the Key to the Bull Market

Let me give you the unassailable themes.

3 Stocks Dragging In The Drugs Industry

3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Bristol-Myers Squibb, Radian and SPDR S&P 500 ETF: Doug Kass' Views

Bristol-Myers Squibb, Radian and SPDR S&P 500 ETF: Doug Kass' Views

Doug Kass shares his thoughts on the condition of the global fixed-income markets.

Everything's Fine and Dandy; Jobs Are in the Rearview Mirror: Jim Cramer’s Best Blogs

Everything's Fine and Dandy; Jobs Are in the Rearview Mirror: Jim Cramer’s Best Blogs

Jim Cramer talks about the post-Brexit world, and how it's now all about the earnings as the jobs report recedes in the distance.

Jim Cramer: Lighten Up, the World Is OK for Now

Jim Cramer: Lighten Up, the World Is OK for Now

The world didn't end two weeks ago, Cramer says, so everyone should just calm down and tune out the pundits.

Cramer: All Is OK With the World, and That's Fine for Now

Cramer: All Is OK With the World, and That's Fine for Now

Brexit wasn't the cataclysmic event many pundits wailed about, and while there is still uncertainty, the market is showing its resilience.

Biotech Stock Mailbag: Heron, Exelixis

Biotech Stock Mailbag: Heron, Exelixis

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Goldman Sachs Recommends These 14 Conviction Buy Stocks for the Rest of 2016

Goldman Sachs Recommends These 14 Conviction Buy Stocks for the Rest of 2016

Goldman Sachs expects "rising uncertainty" in the second half of 2016 and suggests that investors stick to stocks within defensive sectors including consumer, health care and telecom services.

Bristol-Myers (BMY) Stock Slides on Swedish Acquisition

Bristol-Myers (BMY) Stock Slides on Swedish Acquisition

Bristol-Myers (BMY) announced today that it has acquired Swedish-based Cormorant Pharmaceuticals for $520 million.

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based...

'Mad Money' Lightning Round: You Should Be Buying Visa

'Mad Money' Lightning Round: You Should Be Buying Visa

Cramer says Wynn is fantastic but he's avoiding Valeant.

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

When short-sellers get caught leaning the wrong way, that's a recipe for explosive moves to the upside, Cramer says.

How Pfizer, Merck May Feel Long-Term Pinch From Brexit

How Pfizer, Merck May Feel Long-Term Pinch From Brexit

The eventual negative implications of Brexit could be greater for health care companies that have sizable exposure to Europe.

Cramer: Here's What's Behind the Horrible Politics of Brexit

One side lied, one side barely tried, the people voted for economic suicide, but it will not stick.  

Jim Cramer's 'Mad Money' Recap: 'Brexit' Is the Dumbest Financial Mistake Ever

Jim Cramer's 'Mad Money' Recap: 'Brexit' Is the Dumbest Financial Mistake Ever

The true cost of British independence from the EU is now becoming apparent, Cramer says.

KMX, FB, AAPL: Jim Cramer's Views

KMX, FB, AAPL: Jim Cramer's Views

Cramer shares his views on how Brexit is going from molehill to mountain and wonders if anyone cares about market opportunities. Carmax, Facebook and Apple are among the stocks discussed.

Sickle Cell Partnership Creates Demonstration Project To Treat Children In Angola

Sickle Cell Partnership Creates Demonstration Project To Treat Children In Angola

The Angola Sickle Cell Initiative, a public-private partnership of the Angola Ministry of Health, the Baylor College of Medicine International Pediatric AIDS Initiative (BIPAI), Texas Children's Hospital and Chevron, is...

Cramer: Let's Put Brexit in Its Historic Context

This debate is not about EU control of Britain.

Murdo Gordon Appointed Executive Vice President And Chief Commercial Officer

Murdo Gordon Appointed Executive Vice President And Chief Commercial Officer

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Murdo Gordon has been appointed executive vice president and chief commercial officer, a newly created position, effective June 21, 2016.

3 Finds in Biotech's 'Pocket of Value'

Large biotech stocks are still at their cheapest valuations since 2011.